MARCUS NORRIS: Open Payments
NPI 1962591362 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,813 in 136 payments from 39 companies in 2025. Trend: 2023 $688 · 2024 $3,313 · 2025 $2,813
Food & beverage: $2,813
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 6 | $264 |
| Janssen Biotech, Inc. | 14 | $240 |
| AstraZeneca Pharmaceuticals LP | 12 | $232 |
| Novartis Pharmaceuticals Corporation | 13 | $222 |
| GlaxoSmithKline, LLC. | 11 | $178 |
| Merck Sharp & Dohme LLC | 7 | $169 |
| Celgene Corporation | 4 | $106 |
| Eisai Inc. | 6 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $99 |
| Astellas Pharma US Inc | 4 | $95 |
Products named: Trodelvy, KEYTRUDA, Enhertu, CARVYKTI, REBLOZYL, IMFINZI, Lenvima, PLUVICTO.
Industry payments across TN — which companies pay providers there.
